News

About admin-arthurian

This author has not yet filled in any details.
So far admin-arthurian has created 13 blog entries.

PPI
apitope
cequr
interrad
reneuron
sphere
simbec
verona
medaphor

Proton Partners International Annouces New Cancer Centre In North West

Liverpool, 15th March 2017: Proton Partners International has today announced plans to build a new £35 million cancer treatment centre in Liverpool.

Read more

The cancer centre will be built in the new £1 billion Paddington Village, part of Liverpool’s Knowledge Quarter (KQ).

This will be one of four centres built by Proton Partners International in the UK and will make the company the world’s largest developer of proton beam therapy centres. Proton Partners International is currently building three other UK cancer centres, in Newport, Northumberland and Reading, and is considering further sites.

The oncology centre, which will be known as The Rutherford Cancer Centre North West, will offer radiotherapy, chemotherapy and imaging from 2018, and proton beam therapy will be available in 2019.

Joe Anderson, Mayor of Liverpool, said: “We are delighted KQ Liverpool has been able to attract another prestigious development to Paddington Village.

“Momentum is really beginning to build for KQ Liverpool and we can expect more exciting announcements like Proton Partners International’s, which will further cement its reputation as a world leading hub in medical and life sciences research.”

Mike Moran, chief executive officer of Proton Partners International, said: “I am delighted to announce that our fourth UK centre is to be in my home city of Liverpool.

“Not only will we be bringing the top cancer technology to the North West, but we will be located at heart of what will be a world-class destination for science, innovation, education and technology.

This investment will not only enhance the level of cancer treatment available to patients, but will also bring skilled jobs to the area.”

It is expected The Rutherford Cancer Centres will each be able to treat up to 500 patients a year and treatment will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.

Proton Partners International is also building a genomics research centre at the Life Sciences Accelerator building in Liverpool which will be the first part of a health campus set to surround the £335m new Royal Liverpool Hospital. The genomics programme will support Proton Partners International’s broader research work with the University of Liverpool’s Physics Department.

ENDS

Notes to Editors

Contact details

Sophie Watson, Media House International, 0207 710 0020 orSophie@mediahouse.co.uk

Ramsay Smith, Media House International, 0207 710 0020 orRamsay@mediahouse.co.uk

About The Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.

Services will be available to patients under medical insurance self-pay patients and patients referred by the NHS.

About Proton Partners International Ltd

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: http://proton-int.com/

Follow us on twitter @ProtonPartners

About KQ Liverpool

KQ Liverpool is a 450-acre urban innovation district and is home to some of the world’s most influential players in science, health, technology, education, music and the creative and performing arts. With over £1bn of new developments currently underway – and a further £1bn in the pipeline – the plan is to increase the city’s employment figures, improve graduate retention and attraction rates and establish Liverpool at the forefront of the Northern Powerhouse. The unique mix of science, medicine and culture, combined with KQ Liverpool’s stunning architecture and its position at the heart of the city, has already attracted the Royal College of Physicians who have chosen KQ Liverpool as the home for their new Northern Centre of Excellence. The KQ Liverpool team is tasked with defining, creating and promoting the place and occupies the dynamic space between ambition and delivery. We believe that the whole is greater than the sum of its parts, which is why we bring together the city’s key partners to collaborate in a creative environment, allowing us to not only discover and present opportunities but to respond to them quickly. We provide consistent messaging, a single point of contact for investors and businesses and through the ‘power of place’ foster clustering, networking and knowledge transfer. www.KQLiverpool.co.uk

For more information about KQ Liverpool, please contact Michael Doran at Liverpool City Council Newscentre on 0151 233 0074 or 0780 1453918.

Proton partners international announces the rutherford cancer centres

22 February 2017: Proton Partners International has announced today it is to name its clinics The Rutherford Cancer Centres.

Read more

The Rutherford Cancer Centres will offer patients a comprehensive range of cancer treatments and, from 2018, will be the first in the UK to offer high energy proton beam therapy.

The oncology centres have been named to reflect the renowned scientist Ernest Rutherford’s contribution in identifying and naming the proton in 1911.

Three centres are currently under development, in Newport, South Wales, Bomarsund, Northumberland and Reading, Berkshire. The Rutherford Cancer Centre, South Wales is nearing completion and will offer chemotherapy, radiotherapy and imaging via the latest planning and treatment technologies. Positron emission tomography–computed tomography (PET-CT) will be available in the second half of this year and proton beam therapy will be available at the centre from early 2018.

Treatment at The Rutherford Cancer Centres will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.

Professor Gordon McVie, chairman of Proton Partners International, said: “We’re delighted to announce the creation of The Rutherford Cancer Centres.

“Proton Partners International is committed to transforming cancer care in the UK. The Rutherford name is synonymous with a major breakthrough in cancer treatment and therefore we felt that this was a fitting identity for our treatment centres.

“With cancer on the rise, there is a growing need for patients to be offered a holistic and sophisticated level of cancer care.  Patients at The Rutherford Cancer Centres will have access to a wide range of cancer services and a treatment plan will be implemented on an individual basis.”

Mike Moran, chief executive officer of Proton Partners International, said: “We are working with the world’s leading technology partners to ensure that our centres are equipped with the latest cancer technology.

“Our centres will have the capacity to treat 500 unique patients a year. We will also network our centres to ensure the data they will provide can play a significant role in cancer research. We are committed to undertaking a genomics programme which will collate, analyse and distribute data through our research facility at the Life Sciences Accelerator centre in Liverpool.”

Notes to Editors

 Contact details

Sophie Watson, Media House International, 0207 710 0020 or Sophie@mediahouse.co.uk

Ramsay Smith, Media House International, 0207 710 0020 or Ramsay@mediahouse.co.uk

About The Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.

Services will be available to patients under medical insurance self-pay patients and patients referred by the NHS.

About Proton Partners International Ltd

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: http://proton-int.com/

Follow us on twitter @ProtonPartners

Ramsay Smith

Executive Director | Media House International Ltd

t: 0207 710 0020 |​ m:07788 414 856

t: 0141 220 6040 | f: 0141 220 6044

Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis.

Read more
 

The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with relapsing multiple sclerosis. The investigational product was administered intradermally (ID) every 2 weeks for 20 weeks. Following a dose titration of 50 and 200 μg in the initial 4 weeks of treatment a dose of 800μg was administered fortnightly for a further of 16 weeks.

There were statistically significant reductions in total and new T1 Gadolinium enhancing lesions measured using MRI during treatment as well as a significant reduction in the volume of T1 Gadolinium enhancing lesions. The data also showed a strong trend towards improvement in the Multiple Sclerosis Functional Composite (MSFC) score that is used clinically as an indicator of improvement in disability. There were no treatment related serious adverse events and the adverse event profile was mild.

Dr Keith Martin, Chief Executive Officer of Apitope, commented: “We are delighted with these positive results that confirm both clinical findings in our Phase Ib trial as well as preclinical results showing significant decreases in MRI detected lesions and disability in a standard multiple sclerosis model. We will continue to progress the development of ATX-MS-1467 as a treatment for multiple sclerosis and are currently preparing for a Phase IIb placebo controlled study to demonstrate clinical efficacy.”

Dr Jeremy Chataway, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London, commenting on the results said: “Having been the Chief Investigator on the previous Phase Ib study, it is pleasing to see these promising confirmatory Phase IIa results where ATX-MS-1467 has shown both an encouraging efficacy and an excellent safety and tolerability profile. While these patients were only treated for 20 weeks, results in a Phase IIb study with a longer treatment period will be interesting.”

The compound had previously completed a Phase I clinical study in six patients with secondary progressive multiple sclerosis (SPMS) and a second Phase I study in 43 relapsing multiple sclerosis patients, assessing safety and biological parameters. The latest results support the further development of ATX-MS-1467 in multiple sclerosis.

For further information:

Apitope

Dr Keith Martin, CEO

Tel: +44 (0)1291 63 55 11

keith.martin@apitope.com

For media enquiries:

Hume Brophy

Conor Griffin, Alexia Faure, Alexander Protsenko

Tel: +44 (0)20 7862 6381

apitope@humebrophy.com

 About Apitope

Apitope is a European biotech company focused on the discovery and development of disease modifying therapies for abnormal immune responses including autoimmune diseases such as, multiple sclerosis, Graves’ disease, and uveitis; and Factor VIII intolerance

Apitope has a patented discovery platform which enables selection of disease-modifying peptide therapies for the target of interest; and has already generated a pipeline of seven programmes in clinical and preclinical development, of which the lead programme in multiple sclerosis is in Phase II. The discovery engine selects Apitopes™ – Antigen Processing Independent epiTOPES. Apitopes are soluble, synthetic peptides from the human sequence which can selectively suppress abnormal immune responses and reinstate the normal immune balance. Stakeholders in the company include Wales Life Sciences Fund, Vesalius Biocapital, LRM, the Wellcome Trust and the US MS charity, Fast Forward.

About ATX-MS-1467

Apitope’s lead product candidate is ATX-MS-1467, a potentially disease-modifying therapy for the treatment of multiple sclerosis, is a novel peptide-based therapeutic identified using Apitope’s proprietary technology platform.

It consists of four short peptides that are derived from myelin basic protein, a key autoantigen in multiple sclerosis. It is designed to induce immunological tolerance of the body’s T cells to key autoantigens thought to be involved in the pathogenesis of multiple sclerosis.

For more information on the Company, please visit: www.apitope.com 

Alexander Protsenko

Consultant

Hume Brophy | 55 King William Street | London EC4R 9AD | UK

DD +44 (0)20 7862 6397 | T +44 (0)20 7862 6481 | M +44 (0)73 9376 5184

alex.protsenko@humebrophy.com

 

Arthurian life sciences statement on reneuron stroke study results

London, 5th December 2016: Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics.

The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two.
The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment. Three patients registered improvement over a variety of timescales. 15 patients in the 21-person study had a “clinically significant response” on at least one of the three commonly-used scales for assessing improvements following treatment.

Read more

ReNeuron now intends to apply to the US and European regulatory authorities to commence a randomised, placebo-controlled, pivotal clinical trial in patients who are living with disability post-stroke.

Arthurian Life Sciences manages the Wales Life Sciences Investment Fund which made a substantial investment in ReNeuron and attracted the company to Wales.

Professor Sir Christopher Evans, chairman and founder of Arthurian Life Sciences, said: “We are delighted that ReNeuron has reported such encouraging results from its latest study. The treatment has great potential for patients and the company will go into its next trial with confidence. The results of the PISCES II trial are also a real boost for life sciences in Wales.

“These strong Pisces II results follow on from all of the positive safety and efficacy data accumulated over the last three years from the Pisces 1 study. “

Proposed Placing to raise c. £44.7 million (US$63.3 million) and Notice of General Meeting

Capitalised terms in this announcement have the same meaning as in the Circular being published in

conjunction with the proposed placing (unless otherwise indicated) and are also defined below.

17 June 2016, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has successfully secured funding commitments to raise gross proceeds of c. £44.7 million (US$63.3 million), through a conditional placing (the “Placing”) with new and existing investors, including a number of specialist US, UK and European healthcare funds. The Placing was significantly oversubscribed.

The net proceeds of the Placing are expected to fund RPL554 through a Phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional Phase 2 studies in both COPD and cystic fibrosis.

MTS Securities, LLC is acting as the US placement agent and N+1 Singer is acting as the UK broker and nominated adviser in connection with the Placing. The Placing is not being underwritten.

Read more

Highlights

  • The Placing will raise gross proceeds of c. £44.7 million (US$63.3 million) through the issue of 1,555,796,345 Units at a price of 2.873 pence per Unit (each comprising one Placing Share and one Warrant)
  • The net proceeds of the Placing will predominantly be used to progress RPL554 through a Phase 2b clinical trial in COPD patients, and to fund additional clinical Phase 2 studies in COPD and cystic fibrosis as well as further supportive pre-clinical work
  • The funding enables the Company to materially advance the development of RPL554 and build on the significant progress made to date with the revised formulation
  • The cornerstone investors in the Placing are specialist healthcare focused funds Vivo Capital, OrbiMed and Edmond de Rothschild Investment Partners
  • Other new investors include New Enterprise Associates, Novo A/S, Abingworth and

Aisling Capital with participation of existing investors including Arix Bioscience, Hargreave Hale and Polar Capital

  • The Placing Price represents the average closing mid-market price of an Ordinary Share during the five trading days to 15 June 2016, being the last practicable date prior to investors signing their binding Placing commitments
  • Each Warrant will be exercisable into 0.4 of a Warrant Share, at an exercise price per Warrant Share of 3.4476 pence, being 120 per cent. of the Issue Price
  • On or shortly after Admission, representatives from certain of the investors will join the Board as non-executive directors
  • The Company has undertaken to use commercially reasonable efforts to procure a listing on NASDAQ and raise a further tranche of funding in the future

The Placing is conditional upon, amongst other things, approval by existing shareholders at a general meeting to be held at 11.00 a.m. on 22 July 2016 at the offices of Shakespeare Martineau LLP at Allianz House, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR (the “General Meeting”). Admission of the Placing Shares to trading on AIM is expected to take place on 29 July 2016.

Jan-Anders Karlsson, CEO of Verona Pharma, commented:

“We have made significant clinical progress with our first-in-class drug RPL554. This drug has shown the potential to become an important novel and complementary treatment option for patients with COPD, a debilitating and progressive disease that impacts about 65 million people worldwide and is still among the four leading causes of death globally.

“The funds raised from the Placing will allow the Company to focus on conducting a comprehensive Phase 2b clinical trial programme for nebulised RPL554 as a potential treatment for patients with COPD. We will also explore in the clinic for the first time the use of RPL554 as a novel treatment for cystic fibrosis expanding the potential of the drug into another respiratory disease where there remains a significant unmet need. This follows on from the compelling data we have generated in translational, preclinical models of this disease.”

David Ebsworth, Non-Executive Chairman of Verona Pharma added:

“The Board would like to thank both the proposed new and our existing shareholders for their support. Indeed, this powerful syndicate of highly experienced bioscience investors have conducted significant due diligence in the product ahead of investing in the proposed Placing announced today, which we believe further attests to the potential value of RPL554.

“This funding will enable us to progress RPL554 through significant value inflection points. The strength of the data package for the product generated to date gives us confidence that a substantial Placing provides the optimal opportunity to retain maximum value in the Company without compromising our future strategic options.

“A subsequent listing of ADSs on NASDAQ as part of a US IPO for Verona Pharma is a natural evolution in our corporate strategy to focus on the US market opportunity, with its broadly accepted use of nebulisers in the treatment of patients with COPD. It will also allow the Company easier access to a larger pool of investors in the US who have a deep understanding of the healthcare market in which Verona Pharma operates.”

The Company’s lead drug, RPL554, is a dual phosphodiesterase PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties that has the potential to become a novel treatment for patients with obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis and potentially asthma. Furthermore, based on data generated to date, Verona Pharma believes RPL554 can provide relevant clinical and health economic benefits in a commercial setting.

A circular to Shareholders containing, amongst other things, the notice of the General Meeting (the “Circular”) will be published by the Company today and posted to Shareholders. An extract from the Circular is set out below. Copies of the Circular will be available at the Company’s website: www.veronapharma.com.

This announcement should be read in conjunction with the Circular in its entirety, which contains further details on the terms of the Placing and related matters.

CANCER TREATMENT MILESTONE AS PLANS ARE UNVEILED

CANCER TREATMENT MILESTONE AS PLANS ARE UNVEILED FOR UK’S FIRST PROTON BEAM THERAPY CENTRES

April 5th 2015 : The UK is to get its first three Proton Beam Therapy centres, marking a significant breakthrough in the provision of cancer treatment.

Cardiff-based Proton Partners International Ltd is to open the treatment centres in Cardiff, London and Northumberland by 2017 and the first – Cardiff –  will be operational next year.

Read more

The centres will be available for NHS patients from England, Scotland and Wales, medically-insured private patients and self-paying patients.

Proton Partners International has been formed following discussions between Professor Sir Chris Evans, the leading life sciences entrepreneur, and leading UK life sciences and healthcare investors on addressing cancer treatment in the UK. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman and Professor Karol Sikora, has agreed to become chief medical adviser to the company, alongside a range of renowned cancer and healthcare experts.

Professor McVie said: “This is an exciting and important development of the provision of cancer treatment in the UK. As things stand, patients who can benefit from this treatment have to go abroad for treatment, often at great expense to the NHS. The creation of these centres will go a long way to ensuring the very best of treatment is available in the UK.”

Professor Sikora said: “I was delighted to be approached by Sir Chris as there are only 40 Proton Beam Therapy centres around the world and a pressing need for more.  In the UK there are none. Given the ageing population, there will be a significant rise in the number of cancer cases in the UK and therefore we should do what is necessary to provide the appropriate level and type of care.”

Sir Chris Evans and his team at Arthurian Life Sciences, which manages the £100 million Wales Life Sciences Investment Fund established by the Welsh Government, are investing in the company through the fund.

Sir Chris said: “We are delighted that the UK’s first centre will be based in Cardiff and Wales Life Sciences Investment Fund is proud to support this breakthrough. There are more than 150,000 people treated by radiotherapy for cancer each year in the UK and the demand for treatment is growing. It is anticipated that NHS demand for Proton Beam Therapy abroad will reach 1,500 patients by 2017. Proton Partners will be able to play a leading part in helping meet demand in the UK as of next year.”

Edwina Hart, the Minister for Economy, Science and Transport, in the Welsh Government, said:  “I am delighted that Sir Chris and his Arthurian team are bringing this excellent project to Wales to build the first Proton Beam Therapy centre in Britain.”

In addition to state of the art Proton Partners’ treatment services, the Cardiff centre will provide conventional radiotherapy, chemotherapy and supportive care. This could then be offered through other centres.

Proton beam therapy is a highly-targeted type of radiotherapy that can treat hard-to-reach cancers, such as spinal tumours (chordomas), with a lower risk of damaging the surrounding tissue and causing side effects.

In the future, Proton Partners International intends to develop further proton therapy centres in Asia, the Middle East and Africa.

The Government has announced that it is to create two NHS proton beam therapy units which will open in 2018.

 

Notes to Editors:

Proton Partners International is a private limited company, registered in Wales.

Professor Gordon McVie is Senior Consultant at the European Institute of Oncology, Visiting Professor at Glasgow University and Honorary Consultant in Medical oncology at the Welsh Cancer Institute, Cardiff, Wales.

Professor Karol Sikora is former Chief of the World Health Organisation’s Cancer Programme and medical adviser to Cancer Partners UK.

Sir Chris Evans (deputy non-executive chairman) has established high-quality science companies, 20 of which have been taken public and is widely regarded as Europe’s leading life sciences entrepreneur.

Mike Von Bertele CB OBE (non-executive director) is International Director of Save the Children working alongside DfID to combat Ebola in West Africa. Formerly Director General Army Medical Services., he was appointed Honorary Surgeon to Her Majesty The Queen in 2008.

Mike Moran MBE( managing director) has 30 years experience in strategic leadership, planning & programme delivery and has held executive positions in defence and healthcare companies in UK & abroad.

John McIntosh MSc MA (Programme director) has three decades leading healthcare delivery in challenging international environments.

David Knott (Chief Technology Director) is CEO of The MEI Healthcare Group, a 40 year-old healthcare strategy and development group. He has personally led the setting up of 6 such proton centres in the USA.

BUPA estimates that by 2021, the UK’s ageing population is likely to see: 20% rise in the number of new cancer cases to 383,000. 62% rise in the treatment cost to £15.3bn.

 

Further information:

Proton Partners International Ltd

Professor Gordon McVie

Professor Sir Chris Evans

Professor Karol Sikora

The Welsh Life Sciences Investment Fund

Martin Walton

The Welsh Life Sciences Hub

Professor Chris McGuigan, Chairman.   

 

Contact:

Ramsay Smith, Media House 07788414856 / ramsay@mediahouse.co.uk.

Clare Ambrosino 07502971408 / clare@mediahouse.co.uk

 

Arthurian Brings Leading US Medtech Firm to Wales

ARTHURIAN BRINGS LEADING US MEDTECH FIRM TO WALES

December 1st 2014: Arthurian Life Sciences, the specialist fund management company led by  Professor Sir Chris Evans, announced today it has formed a partnership with one of the leading medtech firms in the US, Interrad Medical Inc.

Read more

The Minneapolis-based company is the developer and manufacturer of the unique SecurAcath®, the world’s most effective device for securing catheters in hospital patients.

The partnership is the sixth investment of The Wales Life Sciences Investment Fund, managed by Arthurian which was specifically formed to act as General Partner of the fund.

The fund has made a £3 million investment in Interrad Medical Inc, acting as cornerstone investor in a financing through which the company will establish its European headquarters at the Life Sciences Hub Wales in Cardiff, as a base for sales, marketing, distribution and training.

SecurAcath® is a unique, competition-beating device that in multiple tests has proven to provide significant advantages and cost savings over current securement methods, decreasing time to secure, maintain and remove catheters and essentially removing dislodgement risk. This results in greater patient comfort, saving in nursing time and eliminating the potential for costly needle stick injuries. It is already in use in almost 300 hospitals globally, including Cardiff’s Velindre hospital which reported the overwhelming benefit of the device in prevention of migration.

Interrad will co-ordinate sales and training in 9 European countries initially. Arthurian will assist the company in this expansion, and ultimately into MENA and the Far East. Future plans for Wales include manufacturing, packaging and distribution of SecurAcath, in addition to the development of new products on the platform.

Arthurian Chairman Professor Sir Chris Evans commented:

“The investment in Interrad demonstrates the global reach of my team at Arthurian and the very meaningful impact the Wales Life Sciences Fund can make to the sector in Wales by bringing in the very best of US medical technology, know-how and practices. Advances in medical science and biotech are a global industry affecting everyone in the world, and I am very pleased to be placing Wales at the forefront of that industry”.

Interrad Medical Inc., CEO Joe Goldberger said:

“We are very pleased with this latest investment round, to establish a European headquarters in Cardiff. We look forward to working with Arthurian and the Life Sciences Hub Wales on expanding and growing global sales of the revolutionary SecurAcath device.”

Minister for Economy, Science and Transport Edwina Hart said: “We are delighted to welcome Interrad to Wales, and wish them every success in expanding their sales and distribution from their new European headquarters at Cardiff Bay. Interrad’s decision acknowledges the leading position of Wales in life sciences in Europe and builds on the strong foundation of medtech research, development and production for which Wales is well known. The move also confirms the position of the Life Sciences Hub Wales at the centre of this growing, vibrant and prosperous sector.”

Life Sciences Hub Wales Chairman Professor Chris McGuigan said:

“Wales has some gems of world-leading activity in medical device technology – and this is further strengthened by the great news of the Life Science Fund’s investment in Interrad Medical. Interrad will find a thriving ecosystem in the newly opened Life Sciences Hub and we will warmly welcome them as our 60th member”.

 

About Interrad Medical, Inc.

Plymouth, MN based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices, designed for minimally-invasive interventional and surgical procedures. The Company was founded by practicing Interventional Radiologist and Interrad Medical Chairman and Chief Medical Officer, Michael Rosenberg, M.D. For more information, visit www.securacath.com and download the new SecurAcath App at the App Store or Google Play.

 

About the Life Sciences Hub Wales

The Life Sciences Hub Wales is part of the Welsh Government’s strategy to develop the Life Sciences Sector in Wales. Along with the £100M Life Sciences Investment Fund, the Hub acts as a focus for the sector to encourage collaboration and innovation amongst the life science community.

Opened in July this year, the Life Sciences Hub Wales is creating an ecosystem for Life Sciences in Wales by bringing together universities, businesses (both SMEs and multinationals), clinicians and health boards, government, professional service providers and funders. Located in the heart of Cardiff Bay, the Hub provides high quality meeting, networking and desk space and excellent opportunities for companies to interact and transform early stage ideas into real life projects. After only 5 months of operations, the Hub is over half full with 60 member organisations.

Medical technology firm Medaphor raises £4.7m for planned flotation with investors including Arthurian Life Sciences

wales_online_logo_99x16

Medical technology firm Medaphor raises £4.7m for planned flotation with investors including Arthurian Life Sciences

Aug 18, 2014      By Sion Barry

Read more
Cardiff-based medical technology firm Medaphor has raised £4.7m from institutional investors, including the Welsh Government’s Wales Life Sciences Investment Fund, for its planned flotation on the Alternative Investment Market next week.

Last week the company, whose lead ultrasound training simulator product ScanTrainer enables trainees to literally feel what they see on the computer screen in order to develop the complex mix of cognitive skills and eye-hand movement coordination required to learn all the key ultrasound scanning skills, announced its flotation plans.

The successful fundraising round is now closed.

Stuart Gall, chief executive of university spin-out company MedaPhor Group said: “This is a landmark event for the company and we are grateful to our existing investors, especially IP Group, Finance Wales and founder Professor Nazar Amso, for their support, as well as welcoming our new investors, who include Arthurian Life Sciences Fund (which manages the Welsh Life Sciences Investment Fund on a discretionary basis).

“Medical simulation services continue to grow rapidly and we believe our products have the potential to make us a major player in the ultrasound sector of this exciting market.

“Moving to AIM provides us with the backing and visibility to deliver on our growth strategy.”

Alan Aubrey, chief executive of IP Group, said: “This is a huge achievement for MedaPhor and will enable the company to pursue its growth strategy in its target markets. MedaPhor became part of the IP Group portfolio through our recent acquisition of Fusion IP.

“It is the third IP Group portfolio company to float on AIM this year and a good example of how we continue to support our later-stage portfolio companies.”

Richard Hadden, investment executive at Finance Wales, said: “MedaPhor’s ScanTrainer simulator has been well received in its target markets and we’re delighted that the company now plans to raise new capital to facilitate its ambitious growth plans through AIM.

Finance Wales is a cornerstone investor in MedaPhor.

“We’ve backed the company over a number of investment rounds since 2009, including a recent significant pre-IPO round which has taken our total investment in the company to over £1.5m.”

Sir Christopher Evans, chairman of Arthurian Life Sciences, said: “We have had MedaPhor on our radar since we launched our fund in 2013 and we’re delighted to be partnering and investing with IP Group and Finance Wales on this exciting project.

The company has tremendous potential to capitalise on its early success in both the UK and the USA and we look forward to supporting its future growth and expansion.”

Following Medaphor’s float Arthurian will have a 6% stake in Medaphor. IP Group  will remain the largest individual investor at 47.2%. Finance Wales has a stake of just over 23%.

Professor Nazar Amso, founder of MedaPhor, said: “This is a wonderful accomplishment for MedaPhor and an exciting step towards fulfilling its ambition to be a global innovator in ultrasound simulation and education.

As a founder, I am grateful for Cardiff University and our current investors’ early support, and am delighted that the Company has attracted new major investors in its IPO.”

Cenkos Securities is acting for MedaPhor as nominated adviser and broker in relation to the proposed admission.

Admission to trading on AIM is expected to take place  next week when the company will have an anticipated market capitalisation of £10.1m.

 

insider-media-ltd_logo_100x44

MEDAPHOR RAISES £4.7M IN PLANNED FLOTATION

19 Aug 2014

Cardiff University spin-out MedaPhor has raised £4.7m ahead of its planned flotation on the London Stock Exchange.

The company has developed ScanTrainer, a virtual reality education platform to train students, doctors and sonographers. Trading on the AIM market is expected to begin on 27 August with the company expecting a market capitalisation of £10.1m.

“This is a landmark event and we are grateful to our existing investors for their support, as well as welcoming our new investors,” said Stuart Gall, chief executive of MedaPhor.

“Moving to AIM provides us with the backing and visibility to deliver on our growth strategy.”

MedaPhor is backed by intellectual property developer IP Group, Finance Wales and its founder Professor Nazar Amso. New investors include the Welsh Arthurian Life Sciences Fund.

Amso added: “This is a wonderful accomplishment for MedaPhor and an exciting step towards fulfilling its ambition to be a global innovator in ultrasound simulation and education. I am grateful for Cardiff University and our current investors’ early support, and am delighted that the company has attracted new major investors in its IPO.”

Alan Aubrey, chief executive of IP Group, said: “MedaPhor became part of the IP Group portfolio through our recent acquisition of Fusion IP. It is the third IP Group portfolio company to float on AIM this year and a good example of how we continue to support our later-stage portfolio companies.”

Cenkos Securities is acting for MedaPhor, which has bases in Cardiff and San Diego, as nominated adviser and broker.

Simbec buys its way into late-stage R&D with Orion deal

simbec_logo_99x29  orion_logo_100x53

Simbec Research and Orion Clinical Services Merge

The merger of Simbec Research, the specialist CRO in Early Stage Clinical Development, and ORION Clinical Services, the specialist CRO in Late Stage Clinical Development, is tremendous news for the clinical research sector, the merged company and its employees and Wales.

Read more

The Simbec-Orion Group will be a full service international contract research organisation (CRO) with capabilities in both Early Stage Clinical Development and Late Stage Clinical Development with deep expertise in oncology and rare and orphan diseases.  The Group, with combined revenues of approximately £25m, employs approximately 250 staff and has operations across Europe, Australia and the United States together with capabilities in multiple other territories. Simbec-Orion will maintain its headquarters in the UK based in Merthyr Tydfil, South Wales.

Simbec-Orion will offer its current 65 large and mid-cap pharmaceutical and biotech clients a complete service offering from first in human exploratory clinical pharmacology studies, through Phase II and Phase III studies.  Currently the Group has approximately 90 clinical trials running for clients.  In addition, the Group offers its clients Phase IV post authorisation studies for marketing, observational and post authorisation safety studies (“PASS”).

The merger was completed through the provision of £12.5m of funds raised from the Welsh Arthurian Life Sciences Fund and HSBC Bank plc’s West and Wales Corporate team.

My investment management team at Arthurian Life Sciences first backed Simbec in 2013.  Together with HSBC we are delighted to be leading this transaction and look forward to supporting further acquisitions for the new combined Simbec-Orion Group. There is no shortage of targets which would be an excellent fit for what is a world-leading  CRO.

This is also a proud moment for Wales in that it will be retaining the worldwide HQ for the company and it shows what can be achieved in the life sciences sector. I will be delighted to serve as a non-executive director on the board of Simbec-Orion.

Professor Sir Chris Evans

 

fiercecro_logo_100x16

Simbec buys its way into late-stage R&D with Orion deal

June 23, 2014 | By Damian Garde

Welsh CRO Simbec Research is expanding beyond its focus on early-phase studies, buying up Orion Clinical Services in a move the company says will make it a full-service organization.

The roughly $21.3 million deal will create a combined entity with Phase I-IV capabilities, 250 employees around the world and nearly $43 million in annual revenue, the companies said. The two will do business as Simbec-Orion, take up the former company’s Welsh headquarters while maintaining operations across Europe, Australia and the U.S.

Together, Simbec-Orion has a client roster of 65 large- and mid-cap pharma and biotech companies, and the group has about 90 working studies around the world. The combined company has plans to expand from there, promising to “rapidly pursue further acquisitions” on the hunt for more revenue sources.

“Simbec is proud of its 30-year history of excellence in early-stage clinical development,” Chairman Trevor Jones said in a statement. “We are delighted to complete the merger with Orion, which takes our Welsh-headquartered company onto an international stage and expands its capability into late-stage clinical development.”

The deal follows Simbec’s efforts to strike out on its own, as the CRO used an investment from the Wales Life Sciences Investment Fund to acquire itself from Canada’s Altasciences Group last year.

The Welsh Arthurian Life Sciences Fund, backed by biotech entrepreneur Sir Chris Evans, pitched in to help Simbec buy Orion, and Evans will serve as non-executive board director for the combined company.

 

the_sunday_times_logo_98x18

Biotech veteran back on deal trail

Matthew Goodman Published: 22 June 2014

BIOTECH entrepreneur Sir Chris Evans is spearheading the creation of a new force in clinical research for novel drugs.

Simbec Research, a specialist in conducting early-stage trials on behalf of big pharmaceutical companies, and backed by Evans, is to merge with rival Orion Clinical Services, which carries out later-stage tests.

The enlarged group is expected to pursue further acquisitions in an attempt to become a key player in its field. Evans said: “This is a very good area for consolidation. There are scores of targets, varying from £1m businesses to £80m businesses.”

The market is fragmented with estimates suggesting that there are about 750 companies world-wide working on outsourced drug trials.

Evans will become a non-executive director of the combined research business, which will be run by Ronald Openshaw, the former boss of Plethora, a London-listed healthcare company. Simbec-Orion will be chaired by Trevor Jones, a former director of the Wellcome Foundation.

The merger has been funded with £12.5m from the Arthurian Life Sciences Fund, an Evans vehicle set up to manage the Welsh government’s commitments to the biotech industry, and HSBC.

Simbec-Orion will employ 250 staff and is expected to generate sales this year of about £25m. Bosses hope to grow that to £100m. Its client list stretches to about 65 drug developers, including the largest firms in the industry.